Open innovation to bolster research and development for neglected and emerging infectious diseases
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 1
Abstract
Infections remain a significant cause of disease, disability, and death in developing countries. Unfortunately, many of these infections, including centuries-old neglected diseases such as malaria and newly emerging and re-emerging diseases such as Ebola virus disease (EVD), have limited products available to prevent, diagnose, and treat them. One barrier that hinders the development of these products is neglected and emerging disease experts’ limited access to the biopharmaceutical industry’s small molecules, technologies, and know-how. Conversely, the biopharmaceutical industry’s lack of attention to and expertise in these diseases impedes the development of much-needed products. Organisations are addressing these challenges by developing platforms through which disease experts can access industry’s knowledge and assets. Strategic partnerships are applying a synergistic approach to leverage respective strengths of academia and industry. The following article describes two open innovation platforms, the Pool for Open Innovation against Neglected Tropical Diseases (POINT) and WIPO Re:Search, and two strategic, cross-sector collaborative efforts to develop therapeutics for EVD.
Authors and Affiliations
Jennifer Dent, Katy M. Graef and Paddy Shivanand
Keywords
Related Articles
- EP ID EP679259
- DOI -
- Views 147
- Downloads 0
It pays to promote joint PhD programmes between academia and the private sector
The prosperity of a country is closely related to its level of education to fuel research and innovation. Doctoral graduates have attained the highest education level and should be the key players in research and innovat...
Competencies: A new currency for continuing professional development
“No research without trained researchers” has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects. However, it is often hard to determine the type of training required...
Investigative safety strategies to improve success in drug development
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are t...
The launch of the European Institute for innovation through health data
The European Institute for Innovation through Health Data (i~HD) has been formed as one of the sustainable entities arising from the Electronic Health Records for Clinical Research (EHR4CR) and SemanticHealthNet projects...
A systems approach to enhance clinical research and medicines development
The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clin...